



## **UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026**

February 23, 2026

### **Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET**

PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2<sup>nd</sup>, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations [website](#). Following the live webcast, a replay will be available on the site for approximately 30 days.

### **About UroGen Pharma Ltd.**

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed *RTGel*® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first product is approved to treat low-grade upper tract urothelial cancer, and UroGen's second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.UroGen.com](http://www.UroGen.com) to learn more or follow us on X (Twitter), @UroGenPharma.

### **INVESTOR CONTACT:**

Vincent Perrone  
Senior Director, Investor Relations  
[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)  
609-460-3588 ext. 1093

### **MEDIA CONTACT:**

Cindy Romano  
Director, Corporate Communications  
[cindy.romano@urogen.com](mailto:cindy.romano@urogen.com)  
609-460-3583 ext. 1083



Source: UroGen Pharma Ltd.